Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion

ORLANDO, FL / ACCESS Newswire / August 6, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) ("NexTel" or the "Company") is issuing a clarification regarding statements made during an audio stream hosted yesterday afternoon with @SuperRobotGX. Baylor University Research Agreement Update During the presentation, Dr. Hausman referenced a study evaluating the anti-aging properties of Maxasome Plus in collaboration with Baylor University.

NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC

Strategic Acquisition Positions NexTel at the Forefront of Precision Neuro-Restoration with Xycota's Breakthrough Exosome-Delivered Brain Circuitry Repair Platform and Pending FDA Orphan Drug Designation ORLANDO, FL / ACCESS Newswire / August 5, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI), today announced that it has executed a definitive Letter of Intent (LOI) to acquire 100% of Xycota Biosciences, LLC ("Xycota"), a preclinical biotechnology platform engineering non-psychoactive, precision-targeted therapeutics to physically repair brain circuitry and restore synaptic connectivity. Xycota is advancing a transformative biological interface designed to physically repair damaged neural networks in catastrophic neurodegenerative diseases.